載入中
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
收盤時
US$1.04
−US$0.04 · -3.70%
盤後
US$1.02
−US$0.02 · -1.92%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
日內區間
目前US$1.04
52週區間
目前US$1.04
盤中時間採用ET。市場資料可能有所延遲。
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
日內區間
目前US$1.04
52週區間
目前US$1.04
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 59.3萬 USD | 68.3萬 USD | 48.8萬 USD | 38.6萬 USD | 35.9萬 USD |
| 毛利 | 59.3萬 USD | 68.3萬 USD | 48.8萬 USD | 38.6萬 USD | 35.9萬 USD |
| 研究與開發 | 3532.9萬 USD | 3685.2萬 USD | 3285.7萬 USD | 2710.7萬 USD | 1737.6萬 USD |
| 銷售、一般及管理費用 | 1422.4萬 USD | 1248.2萬 USD | 1304.3萬 USD | 1318.1萬 USD | 1183.8萬 USD |
| 營業費用 | 4955.3萬 USD | 4933.4萬 USD | 4590萬 USD | 4028.8萬 USD | 2921.4萬 USD |
| 利息收入 | 310.4萬 USD | 325.9萬 USD | 406.9萬 USD | 158.1萬 USD | 26.4萬 USD |
| 折舊和攤銷 | 90.4萬 USD | 40.4萬 USD | 39.8萬 USD | 23.6萬 USD | 45.1萬 USD |
| 營業利益 | −4896萬 USD | −4865.1萬 USD | −4541.2萬 USD | −3990.2萬 USD | −2885.5萬 USD |
| 淨利 | −4585.1萬 USD | −4543.1萬 USD | −4144.1萬 USD | −3870.4萬 USD | −2829.1萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$2.00
上漲空間 92.31%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年2月20日 | 1:6 | — | — |
股票分割 | 2018年6月4日 | 1:12 | — | — |
股票分割 | 2012年5月30日 | 1:6 | — | — |
股票分割 | 2004年7月27日 | 111:1 | — | — |
已生效 2019年2月20日
1:6
已生效 2018年6月4日
1:12
已生效 2012年5月30日
1:6
已生效 2004年7月27日
111:1
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
